These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. The trial use of clozapine for abnormal involuntary movement disorders. Caine ED; Polinsky RJ; Kartzinel R; Ebert MH Am J Psychiatry; 1979 Mar; 136(3):317-20. PubMed ID: 154301 [TBL] [Abstract][Full Text] [Related]
63. Hyponatremia during treatment with clomipramine, perphenazine, or clozapine: study of therapeutic drug monitoring samples. Spigset O; Hedenmalm K J Clin Psychopharmacol; 1996 Oct; 16(5):412-4. PubMed ID: 8889918 [No Abstract] [Full Text] [Related]
64. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Farde L; Nordström AL Br J Psychiatry Suppl; 1992 May; (17):30-3. PubMed ID: 1358126 [TBL] [Abstract][Full Text] [Related]
66. Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment. Hu XT; Wang RY Brain Res; 1989 May; 486(2):325-33. PubMed ID: 2786442 [TBL] [Abstract][Full Text] [Related]
67. Effects of clozapine on CSF homovanillic acid in spasmodic torticollis. Thiel A; Dressler D; Reimer A; Rüther E J Neural Transm Gen Sect; 1994; 97(3):245-51. PubMed ID: 7873132 [TBL] [Abstract][Full Text] [Related]
68. Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment. Banki CM Psychopharmacology (Berl); 1978 Mar; 56(2):195-8. PubMed ID: 417371 [TBL] [Abstract][Full Text] [Related]
69. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Hansen LB; Larsen NE; Vestergård P Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071 [TBL] [Abstract][Full Text] [Related]
70. Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation. Lindholm H; Ljungberg L Acta Psychiatr Scand Suppl; 1973; 246():52-6. PubMed ID: 4520279 [No Abstract] [Full Text] [Related]
75. Mechanisms of action of clozapine in the treatment of neuroleptic-resistant and neuroleptic-intolerant schizophrenia. Deutch A Eur Psychiatry; 1995; 10 Suppl 1():39s-46s. PubMed ID: 19698391 [TBL] [Abstract][Full Text] [Related]
76. Clozapine--pharmacokinetic investigations and biochemical effects in man. Ackenheil M Psychopharmacology (Berl); 1989; 99 Suppl():S32-7. PubMed ID: 2682731 [TBL] [Abstract][Full Text] [Related]
77. Clozapine: a new antipsychotic drug. Hamilton D Arch Psychiatr Nurs; 1990 Aug; 4(4):278-81. PubMed ID: 2241248 [TBL] [Abstract][Full Text] [Related]
78. THE COMPARATIVE EFFECTIVENESS OF AMITRIPTYLINE, PERPHENAZINE, AND THEIR COMBINATION IN THE TREATMENT OF CHRONIC PSYCHOTIC FEMALE PATIENTS. HANLON TE; NUSSBAUM K; WITTIG B; HANLON DD; KURLAND AA J New Drugs; 1964; 4(1):52-60. PubMed ID: 14157086 [No Abstract] [Full Text] [Related]
79. Effect of clozapine on psychotic depression and parkinsonism. Parsa MA; Ramirez LF; Loula EC; Meltzer HY J Clin Psychopharmacol; 1991 Oct; 11(5):330-1. PubMed ID: 1765577 [No Abstract] [Full Text] [Related]
80. Perphenazine-Associated Nausea: A Case of Protracted Withdrawal. Singh N; Sood N; Jolly T J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):606-608. PubMed ID: 34369907 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]